Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharma Access To Prescribing Data Could Decline Under New AMA Policy

Executive Summary

The American Medical Association is instituting a data restriction program to address growing concern about the appropriate use of physician prescribing information

You may also be interested in...



Pharma Sales Rep Licensure Bill Progresses In D.C. Council

Washington, D.C., could be the first jurisdiction in the country to require by law the licensure of pharmaceutical sales representatives

Pharma Sales Rep Licensure Bill Progresses In D.C. Council

Washington, D.C., could be the first jurisdiction in the country to require by law the licensure of pharmaceutical sales representatives

New Hampshire Prescribing Data Law Shot Down; Other States Pursuing Bills

Several states are continuing to push forward legislation to ban the commercial use of physician prescribing information despite a New Hampshire judge's ruling that the prohibition is a violation of the First Amendment

UsernamePublicRestriction

Register

ID1132956

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel